Author/Authors :
Huang, D. B. Motif BioSciences, Princeton, NJ, USA , Noviello, S. Motif BioSciences, Princeton, NJ, USA , Gemmell, C. G. Division of Infection - Inflammation and Immunology - University of Glasgow Medical School, Glasgow, UK
Abstract :
Staphylococcus aureus is the most common non-gonococcal aetiology of septic arthritis. The efficacy of iclaprim against S. aureus LS-1, a clinical strain identified from a patient with septic arthritis, was studied in MF1 mice to evaluate the activity of iclaprim, which is in clinical development, in preventing joint infections. Iclaprim (2.5–80 mg kg− 1) administered as a single dose via the tail vein reduced the incidence of S. aureus septic arthritis and mortality in an experimental murine model of septic arthritis.
